{"id":34133,"date":"2025-05-26T15:03:24","date_gmt":"2025-05-26T07:03:24","guid":{"rendered":"https:\/\/flcube.com\/?p=34133"},"modified":"2025-05-26T15:03:25","modified_gmt":"2025-05-26T07:03:25","slug":"elpiscience-files-for-hong-kong-ipo-focusing-on-immunotherapy-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34133","title":{"rendered":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline"},"content":{"rendered":"\n<p>China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company&#8217;s aim to expand capital markets and further develop its immunotherapy pipeline.<\/p>\n\n\n\n<p><strong>Company Overview<\/strong><br>Elpiscience, founded in 2017, is a clinical-stage biopharmaceutical company focusing on next-generation immunotherapies. Its lead candidate, the OX40-antibody ES102, licensed from US biotech firm Inhibrx, targets patients with poor response to checkpoint inhibitors. Clinical studies have shown that the combination of ES102 and PD-1 inhibitor demonstrates anti-tumor activity and good safety in patients with PD-1 inhibitor-resistant non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC).<\/p>\n\n\n\n<p><strong>Financial Performance<\/strong><br>In 2024, Elpiscience generated revenue of RMB 107 million (USD 15 million) and reported a loss of RMB 88 million (USD 12 million). This financial performance underlines the company&#8217;s ongoing commitment to advancing its innovative therapies while navigating the challenges of clinical development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/sehk25052301803_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk25052301803_c.\"><\/object><a id=\"wp-block-file--media-cd1d1de3-ada4-4e25-9aec-791bb1068d13\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/sehk25052301803_c.pdf\">sehk25052301803_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/sehk25052301803_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cd1d1de3-ada4-4e25-9aec-791bb1068d13\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34135,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[602,72],"class_list":["post-34133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-elpiscience-biopharmaceuticals","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company&#039;s aim to expand capital markets and further develop its immunotherapy pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34133\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline\" \/>\n<meta property=\"og:description\" content=\"China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company&#039;s aim to expand capital markets and further develop its immunotherapy pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34133\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-26T07:03:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-26T07:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline\",\"datePublished\":\"2025-05-26T07:03:24+00:00\",\"dateModified\":\"2025-05-26T07:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133\"},\"wordCount\":171,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2612.webp\",\"keywords\":[\"Elpiscience Biopharmaceuticals\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34133#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34133\",\"name\":\"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2612.webp\",\"datePublished\":\"2025-05-26T07:03:24+00:00\",\"dateModified\":\"2025-05-26T07:03:25+00:00\",\"description\":\"China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company's aim to expand capital markets and further develop its immunotherapy pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34133\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2612.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2612.webp\",\"width\":1080,\"height\":608,\"caption\":\"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34133#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company's aim to expand capital markets and further develop its immunotherapy pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34133","og_locale":"en_US","og_type":"article","og_title":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline","og_description":"China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company's aim to expand capital markets and further develop its immunotherapy pipeline.","og_url":"https:\/\/flcube.com\/?p=34133","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-26T07:03:24+00:00","article_modified_time":"2025-05-26T07:03:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34133#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34133"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline","datePublished":"2025-05-26T07:03:24+00:00","dateModified":"2025-05-26T07:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34133"},"wordCount":171,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34133#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp","keywords":["Elpiscience Biopharmaceuticals","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34133#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34133","url":"https:\/\/flcube.com\/?p=34133","name":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34133#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34133#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp","datePublished":"2025-05-26T07:03:24+00:00","dateModified":"2025-05-26T07:03:25+00:00","description":"China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKEX), with CITIC Securities acting as the sole sponsor. This move signals the company's aim to expand capital markets and further develop its immunotherapy pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34133#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34133"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34133#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp","width":1080,"height":608,"caption":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34133#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2612.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34133"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34133\/revisions"}],"predecessor-version":[{"id":34136,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34133\/revisions\/34136"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34135"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}